The SEZ6L (Seizure-related 6 homolog-like) antibody is a tool used to study the SEZ6L protein, a member of the seizure-related protein family implicated in neuronal development and synaptic function. SEZ6L is a transmembrane or secreted glycoprotein expressed predominantly in the central nervous system, with roles in neuronal differentiation, axon guidance, and synapse formation. It interacts with extracellular matrix components and signaling receptors, influencing neural network plasticity. Recent studies also link SEZ6L to cancer, particularly in glioblastoma and neuroblastoma, where its overexpression correlates with tumor progression and poor prognosis. The SEZ6L antibody enables detection and localization of the protein in tissues or cell lines, aiding research into its physiological and pathological mechanisms. Commercial SEZ6L antibodies are typically developed using immunogens derived from conserved regions of human or murine SEZ6L, validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. Its emerging association with neurodegenerative diseases and malignancies highlights its potential as a biomarker or therapeutic target, driving continued interest in functional studies using SEZ6L-specific antibodies.